

Appointment of Non-Executive Director

Sydney — 10 December 2018 — ImExHS Limited [ASX: IME] [IME or the Company] is pleased to announce that it has today appointed Dr Douglas Lingard as a Non-Executive Director of the Company.

Doug is an experienced Radiologist and Nuclear Physician who has worked in various leadership roles in Auckland, Washington DC and Sydney. In Australia he was a co-founder of Pittwater Radiology Partners which after a series of mergers and acquisitions listed on the ASX in mid-2000 as Medical Imaging Australasia Ltd (MIA) and became the largest supplier of radiology services in Australia and a major supplier of diagnostic imaging to the NHS in the United Kingdom. In mid-2004, MIA was acquired by DCA Group Ltd for A\$700m to become one of the world's largest radiology businesses, and the leading practice in Australia known as I-Med.

Doug has a medical degree MB.ChB from Otago University, NZ, and was a National Institutes of Health Fellow in Washington DC. He is presently a Fellow of the Royal Australia & NZ College of Radiologists, a Senior Associate of FinSIA and a member of the Australian Institute of Company Directors. He is the founder and present Chairman of the Mito Foundation, the peak charity in Australia for people with mitochondrial disease.

Chairman of the Company, Mr Tom Pascarella said “We are very pleased to have someone with Doug’s local and global radiology experience and stature on the board. Doug will complement the board with his technical expertise and especially his practice management experience as one of IME’s founding principles is to offer innovative imaging productivity tools ‘created by Radiologists for Radiologists’. We welcome Doug to the board and look forward to his contributions to the ongoing validation of our innovations and growth strategies into new geographies and verticals.”

Dr Lingard stated “I welcome the chance to become involved in a company with disruptive, cutting edge technology like ImExHS. Medicine around the world is changing rapidly and joining ImExHS gives me the opportunity to help ImExHS navigate and capitalize on these changes in areas I know well and greatly enjoy”.

Upon his appointment, Dr Lingard or his nominee will be granted 2 million options, with an exercise price of \$0.053. The options will be subject to the following vesting conditions:

- 0.5 million - two years from date of appointment; and
- 1.5 million - three years from date of appointment.

(in each case, subject to Dr Lingard’s continuous service to the Company as a Non-Executive Director from the date of appointment up to and including the applicable vesting date). The options will expire 5 years from the date of appointment.

ENDS-

For more information, please contact:



ASX ANNOUNCEMENT
COMPANY ANNOUNCEMENT

Australian Media and Business Enquiries

Tom Pascarella - Chairman

ImExHS Limited

T: +61 (0) 407 890 933

E: tom.pascarella@allenpartners.com.au

ABOUT IMEXHS

ImExHS Limited [ASX: **IME**] is a leading imaging Software as a Service (SaaS) and ancillary service provider in Latin America. Founded in 2012, ImExHS has become one of the leaders in the Latin American imaging services market, offering flexible and scalable imaging solutions via its HIRUKO branded suite of solutions for next generation Picture Archiving and Communications System (PACS) and integrated Radiology Imaging System (RIS). The HIRUKO system is completely cloud based, vendor neutral and zero footprint with no need for installed software. Enhanced features such as a fully web-based voice recognition option and a zero footprint DICOM viewer are some of its advanced features. In addition to PACS and RIS, imaging technology and management systems can be provided on a Platform as a Service (PaaS) basis. The ImExHS products are designed to save money for the users, with a scalable platform that is configured for the future, while enhancing patient outcomes. Please see www.imexhs.com